/

Società

Ne

Non verificato

Neuraptive Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIgiene alimentareIndustriaSalute

3 comunicati stampa

Guarda tutti i comunicati

14/07/2026

Mercato del lavoro

Industria

Attrezzature medico-sanitarie

Salute

Sanità

Farmaceutica

Biotecnologia

Neuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. Louis

Fonte

Neuraptive Therapeutics, Inc.

Emittente

1.00

0

02/10/2025

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Difesa / Forze Armate

Industria

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

Fonte

Neuraptive Therapeutics, Inc.

Emittente

1.00

0

11/09/2024

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

Fonte

Neuraptive Therapeutics, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0